Investor Presentaiton slide image

Investor Presentaiton

Financial Forecasts for FY2023 Revenue of Major Products in North America & China Change FY2022 Results FY2023 Forecasts Change FY2022 Results FY2023 Forecasts Value FX impact % North America Million $ Billions of yen ORGOVYXⓇ 182 396 214 24.7 51.5 26.8 (2.2) MYFEMBREEⓇ 33 192 159 4.5 24.9 20.4 (1.1) 108.5 454.1 GEMTESAⓇ 182 362 180 24.7 47.0 22.3 (2.0) 90.5 APTIOMⓇ 249 273 24 33.7 35.5 1.8 (1.5) 5.3 RETHYMICⓇ 33 54 21 4.4 7.0 2.6 (0.3) 57.7 LATUDAⓇ 1,465 161 (1,304) 198.5 20.9 (177.6) (0.9) (89.5) Others 280 167 (113) 38.0 22.0 (16.0) (0.9) (42.0) Total 2,424 1,605 (819) 328.5 208.8 (119.7) (8.8) (36.4) China Million RMB Billions of yen MEROPENⓇ 1,445 958 (487) 28.5 18.7 (9.8) (0.2) (34.5) Others Total 550 737 187 10.9 14.3 3.4 1,995 1,695 (300) 39.4 33.0 (6.4) (0.4) (0.2) 31.6 (16.2) * Lump-sum revenue included in "Others" FY2022 Deferred revenue from the collaboration with Pfizer of $138M Revenue from the license agreement for ORGOVYX® of $50M FY2023 Deferred revenue from the collaboration with Pfizer of $117M North America segment Due to loss of exclusivity of LATUDAⓇ in February 2023, revenue will decrease significantly in FY2023 ORGOVYXⓇ and MYFEMBREEⓇ will accelerate the efficiency of sales activities with the acquisition of Myovant as a wholly owned subsidiary ■GEMTESAⓇ is expected continued steady growth ■ KYNMOBIⓇ and LONHALAⓇ MAGNAIRⓇ have been decided to discontinue sales China segment Revenue of MEROPENⓇ will be expected to decrease due to the growing impact of Volume-Based Procurement application FX rates: FY2022 Results : 1US$ ¥135.51, 1RMB = \19.75 FY2023 Forecasts: 1US$ = ¥130.00, 1RMB = \19.50 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 14
View entire presentation